Question  How can adaptive platform trials be designed for nephrology?

Findings  The Global Kidney Patient Trials Network (GKPTN) registry has enrolled 4334 patients with chronic kidney disease since May 2020 across 119 sites in 8 countries. The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect (CAPTIVATE) is a platform randomized clinical trial that includes patients with chronic kidney disease and intends to identify new therapeutic options and clinical trial innovations to efficiently test combination therapies using bayesian approaches and trial simulations to estimate sample size.

Meaning  The GKPTN registry and the CAPTIVATE trial could find new treatments for people with kidney disease and change how trials are conducted in patients with kidney disease.

Source: The JAMA Network